KYLEENA Drug Patent Profile

Which patents cover Kyleena, and when can generic versions of Kyleena launch?

Kyleena is a drug marketed by Bayer Hlthcare and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-seven patent family members in thirty countries.

The generic ingredient in KYLEENA is levonorgestrel. There are twenty drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the levonorgestrel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kyleena

A generic version of KYLEENA was approved as levonorgestrel by NOVEL LABS INC on February 22^nd, 2013.

Summary for KYLEENA

International Patents:	77
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	108
Clinical Trials:	3
Patent Applications:	5,184
Drug Prices:	Drug price information for KYLEENA
What excipients (inactive ingredients) are in KYLEENA?	KYLEENA excipients list
DailyMed Link:	KYLEENA at DailyMed

See drug prices for KYLEENA

Recent Clinical Trials for KYLEENA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Arkansas Children's Hospital Research Institute	Phase 4
Biós Farmacêutica	Phase 2
Science Valley Research Institute	Phase 2

See all KYLEENA clinical trials

Pharmacology for KYLEENA

Drug Class	Progestin Progestin-containing Intrauterine System
Physiological Effect	Inhibit Ovum Fertilization

US Patents and Regulatory Information for KYLEENA

KYLEENA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	KYLEENA	levonorgestrel	SYSTEM;INTRAUTERINE	208224-001	Sep 16, 2016		RX	Yes	Yes			Y
Bayer Hlthcare	KYLEENA	levonorgestrel	SYSTEM;INTRAUTERINE	208224-001	Sep 16, 2016		RX	Yes	Yes
Bayer Hlthcare	KYLEENA	levonorgestrel	SYSTEM;INTRAUTERINE	208224-001	Sep 16, 2016		RX	Yes	Yes			Y

Expired US Patents for KYLEENA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	KYLEENA	levonorgestrel	SYSTEM;INTRAUTERINE	208224-001	Sep 16, 2016

International Patents for KYLEENA

See the table below for patents covering KYLEENA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2009294545
Brazil	PI0919071
Canada	2736020
China	102159162
Denmark	2349143
European Patent Office	2349143
Spain	2424984

Supplementary Protection Certificates for KYLEENA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521	39/2015	Austria		PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521	15C0050	France		PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
1453521	C201630040	Spain		PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211

KYLEENA (levonorgestrel intrauterine system) market dynamics and financial trajectory: pricing, uptake drivers, competitive pressure, and IP/regulatory overhang

Last updated: July 25, 2026

KYLEENA (levonorgestrel IUS 19.5 mg, Bayer) is a mid-to-high penetration branded contraceptive IUD in the US, with demand driven by payer coverage of long-acting reversible contraception (LARC), provider adoption, and persistence. Financial trajectory is shaped by (1) substitution risk from lower-cost branded and generic-available levonorgestrel IUS competitors depending on market, (2) managed-care contracting and rebate intensity, and (3) the absence of direct FDA “exclusivity-like” shocks that typically catalyze rapid generic displacement. The longer-term profile is more exposed to replacement-cycle behavior (5-year vs 3-year IUDs) and to formulary positioning than to classic small-molecule generic erosion.

KYLEENA market size and trajectory: where does demand come from, and how fast is it growing?

Featured snippet answer: KYLEENA demand tracks the US LARC market and intrauterine device adoption, with revenue driven by per-device sales and replacement-cycle replacement rates every 5 years.

What drives KYLEENA adoption in managed care and clinics?

Key demand levers are structural rather than pharmacodynamic. For levonorgestrel IUS products, uptake depends on:

• Net price after rebates driven by payer coverage policy for LARC devices
• Clinical adoption by OB/GYN and family planning networks (training, insertion capacity, complication management)
• Patient preference for a lower-systemic hormonal profile and “set-and-forget” contraception
• Contraceptive counseling timing aligned to annual well-woman care and post-partum care patterns
• Formulary status and site-of-care dynamics (buy-and-bill vs pharmacy benefit coverage where applicable)

What determines revenue persistence for KYLEENA?

KYLEENA’s revenue is largely a replacement-cycle product:

• Initial uptake determines the installed base.
• Persistence and removal behavior determines churn.
• Replacement timing (within the device labeled life) determines re-order cadence and the floor for future sales.

A sustained installed base dampens revenue volatility but does not prevent gradual net-price pressure as payers and providers optimize across IUS product portfolios.

What is the pricing and reimbursement environment for KYLEENA in the US?

Featured snippet answer: KYLEENA’s gross-to-net economics in US contraceptives are primarily a function of payer contracting, rebate intensity, and device-channel mix (commercial vs Medicaid/eligible LARC coverage tiers), which determines realized net revenue per IUD.

Channel mechanics that influence net revenue

1. Payer coverage and PA rules
   Coverage policies for contraception devices often vary by plan design. When PA requirements tighten or coverage narrows, uptake shifts toward preferred products.
2. Rebate intensity and volume commitments
   In contraceptive device categories, formulary preference can be supported by rebates. Net price can fall even if list price remains stable.
3. Site-of-care distribution
   Device supply chain and billing model (clinic purchase vs pharmacy procurement) change who bears acquisition cost and how quickly contracting impacts volume.

Competitive price pressure typically looks like

• Formulary switching toward the lowest net-cost option in the same category
• Increased pressure from alternative LARC devices (including competing levonorgestrel IUS strengths and copper IUDs depending on patient segment)
• Promotional contracting by the incumbent manufacturer ahead of high-volume seasonal cycles in women’s health

Which products compete with KYLEENA, and how does that change market share and margins?

Featured snippet answer: KYLEENA competes in the levonorgestrel IUS segment against other branded levonorgestrel IUDs and, in parts of the market, against LARC alternatives like copper IUDs, with share driven by net price, dosing interval perceptions, and payer formulary positioning.

Competitive set (US contraception IUS ecosystem)

KYLEENA’s closest competitive pressure is from other levonorgestrel intrauterine systems with different labeled duration, hormone release profiles, and branded packaging.

• Lower-dose and duration variants that may be preferred by certain payers or provider formularies
• Higher-dose levonorgestrel IUS products that can win for perceived bleeding profile outcomes in segments that strongly value amenorrhea rates
• Non-hormonal copper IUDs that can win for patients seeking hormone-free contraception

How competition impacts financial trajectory

Competition influences two variables:

• Volume: formulary switching shifts insertions away from KYLEENA when net cost and covered duration align better with competitors.
• Gross margin: rebate-driven net price compression and promotional intensity reduce realized margins even if volume holds.

What do adoption curves and persistence imply for KYLEENA’s future revenue?

Featured snippet answer: KYLEENA’s future growth is constrained by replacement-cycle timing and by how quickly competitors gain installed base; net growth depends on incremental insertions outpacing churn to alternative IUS options.

Installed-base math (how markets typically evolve)

For IUS products, the revenue curve is determined by:

• Annual new starts (insertions)
• Annual removals (early removals plus at/near end-of-life replacement behavior)
• Replacement selection (device chosen for re-initiation)

If competitor share rises among replacement candidates, KYLEENA can see “new uptake slowdown” even with stable installed-base sizes.

Where upside can come from

• Expansion of covered LARC benefits and broader payer acceptance
• Provider network growth and insertion capacity expansion
• Segment-specific positioning through counseling (bleeding profile expectations, menstrual management)

Where downside risk typically appears

• Formulary preference changes
• Increased switching at replacement due to net price or favored patient outcomes
• Contracting setbacks in large managed-care plans

What is the FDA and label framework for KYLEENA, and does it constrain growth?

Featured snippet answer: KYLEENA is an FDA-approved levonorgestrel intrauterine system for contraception with a labeled wear period (commonly marketed as 5 years in the US), which sets the replacement cycle and limits “frequency of purchases” compared with shorter-duration products.

Label duration and market impact

The labeled duration is a central commercial lever:

• Longer wear periods reduce annual replacement demand per patient.
• Sales can still grow with population-level uptake, but revenue growth rate decelerates as the installed base matures.

How label-driven constraints interact with competitors

If a competitor has a more favorable net-cost position at similar duration, or if payers prefer a specific product for menstrual management outcomes, replacement decisions can shift.

Does KYLEENA have generic or biosimilar displacement risk?

Featured snippet answer: KYLEENA is a device-based branded product; displacement risk is driven by competition among other branded IUS products rather than by classic small-molecule generic entry.

Generic entry does not work like oral contraceptives

An IUS is not a typical “generic tablet” pathway. Market displacement typically happens via:

• New branded products
• Contracting changes among existing branded competitors
• Switching behavior at replacement intervals

Litigation and Paragraph IV analogs are not the central driver

For contraceptive IUS devices, the market is more often shaped by business contracting, device differentiation, and regulatory approvals of competing products than by generic patent challenges common in small-molecule drug categories.

What patents protect KYLEENA, and how does patent estate affect the competitive timeline?

Featured snippet answer: The KYLEENA competitive timeline is shaped by the protection of formulation, device design, and manufacturing/process elements, plus method-of-use concepts tied to contraceptive efficacy. The practical effect is that direct device “copying” tends to be delayed until relevant protections expire or design-around space clears.

Patent estate mechanics that matter for market dynamics

• Device structural protection (e.g., dimensions, release components, insertion system)
• Hormone content and release-rate engineering
• Manufacturing methods that can slow technical and regulatory replication
• Implied exclusivity windows from regulatory and device-specific IP rather than small-molecule “Orange Book” generic triggers

Key regulatory milestones that influence KYLEENA commercial performance

Featured snippet answer: Regulatory milestones influence uptake primarily at launch or when label updates expand market permissions; ongoing growth is more sensitive to payer contracting than to periodic regulatory changes.

FDA approval and label stability

Once a device is established and label language is stable, commercial performance becomes dominated by:

• Distribution contracts
• Reimbursement/coverage decisions
• Competitive formulary positioning
• Provider experience and switching behavior

What is KYLEENA’s competitive positioning versus other IUS products?

Featured snippet answer: KYLEENA competes on a balance of labeled duration, levonorgestrel dose characteristics, insertion convenience, and payer-driven net cost. Share shifts when payers and provider groups designate preferred products.

Segments most likely to shift

• Patients with strong plan-based incentives toward preferred LARC devices
• Clinics that standardize on fewer IUS SKUs to reduce procedural variation
• Replacement candidates where formulary preference becomes the dominant decision variable

Settlement, litigation, and commercial contracting: what matters for financial trajectory?

Featured snippet answer: In contraceptive device markets, the most consequential “legal” events for financial trajectory are those that change competitive access through injunctions or that alter availability and contracting. Absent a public injunction, market outcomes largely track contracting and competition.

What to watch in future quarters

• Changes in major payer preferred drug/device lists for LARC
• Contracting outcomes with large buying groups and health systems
• Product availability signals that force short-term substitutions

Revenue sensitivity: what would most likely move KYLEENA sales up or down?

Featured snippet answer: KYLEENA sales are most sensitive to formulary changes, rebate-driven net pricing, replacement choice after the initial 5-year cycle, and changes in the volume of LARC insertions in the covered population.

Most material downside indicators

• Broad payer downgrades or preferred-product switches
• Rebate or contracting losses in large managed-care segments
• Faster-than-expected switching at replacement due to competitor advantage

Most material upside indicators

• Expanded coverage for LARC devices
• Preferred position upgrades on payer formularies
• Clinic and provider network expansion with high insertion volumes

Geographic dynamics: where is KYLEENA most exposed?

Featured snippet answer: KYLEENA’s financial trajectory is most exposed in geographies where LARC reimbursement models are more restrictive or where payer preferred-device selection is aggressively negotiated.

US versus ex-US commercialization

Device contraception markets are frequently fragmented by:

• reimbursement frameworks and coverage mandates
• clinic procurement practices
• local competition sets by product and duration

Key takeaways

• KYLEENA’s financial trajectory is driven by LARC adoption, replacement-cycle dynamics, and payer contracting rather than by classic small-molecule generic displacement.
• Competitive pressure is mainly from other levonorgestrel IUS branded options and from managed-care formulary positioning that governs net price and selection at insertion and replacement.
• Longer labeled duration supports revenue stability from the installed base but slows per-patient purchase frequency, making growth dependent on new starts and replacement switching.
• The dominant watchpoints for near-to-mid term financial performance are preferred formulary status, rebate intensity, and clinic standardization across IUS SKUs.

FAQs

1. How does KYLEENA’s labeled wear period affect replacement-cycle revenue compared with 3-year levonorgestrel IUS products?
2. What drives KYLEENA switching decisions at time of replacement: net cost, provider preference, or bleeding profile outcomes?
3. How do managed-care formulary changes for LARC devices translate into measurable volume impacts for KYLEENA?
4. What competitive factors determine whether KYLEENA is preferred in health-system contract formularies?
5. Does KYLEENA’s device-based IP structure create different competitive timing versus small-molecule patent estates?

References

1. FDA. KYLEENA (levonorgestrel) prescribing information and label information. U.S. Food and Drug Administration.
2. U.S. FDA, Orange Book. KYLEENA listings and related regulatory documentation, if applicable. U.S. Food and Drug Administration.
3. Bayer. KYLEENA product information and US commercialization materials. Bayer.

DrugChatter Q&A for KYLEENA

How much does kyleena cost in canada?